BioAlliance Pharma SA (Euronext Paris – BIO), a company
dedicated to the supportive care and treatment of cancer patients, presented the results of the
pharmacokinetic study on its Sitavir® (acyclovir Lauriad® 50mg), developed for the treatment of
recurrent oro-facial herpes, at the “FIP Pharmaceutical Sciences World Congress (PSWC)
2010 in association with the AAPS (American Association of Pharmaceutical Scientists)
Annual Meeting and Exposition”.
This pharmacokinetic study showed that after one single application of Sitavir® mucoadhesive
buccal tablet, acyclovir concentrations in saliva and labial mucosa were rapidly detected
(within 30 minutes). These concentrations on the muco-cutaneous infection site have been
sustained over 24 hours whereas plasma concentrations were very low. These results support
the administration of one single dose of Sitavir® as soon as the first oro-facial herpes infection
symptoms or signs occur. The efficacy of one single dose of Sitavir® for the treatment of
recurrent oro-facial herpes has been confirmed in the pivotal phase III clinical trial including
over 700 patients.
“These data confirm the interest of mucosal targeting obtained with our mucoadhesive buccal
Lauriad® technology”, comments Dominique Costantini, Chief Executive Officer of
BioAlliance Pharma. “This technology, protected by several families of patents over the long
term, has enabled us to develop two innovative products: Loramyc® (Oravig® in the US),
dedicated to the treatment of oropharyngeal fungal infections and registered in 28 countries,
and Sitavir®, dedicated to the treatment of recurrent herpes labialis infections whose
registration dossier submission is planned in 2011. Today, with two other innovative products
already in clinical phase, fentanyl Lauriad® and clonidine Lauriad®, BioAlliance is capitalizing
on its mucosal know-how and on the good tolerance observed. The company is accelerating
the development of products in new markets, opening the path to additional revenues”.